DaVita Management

Management criteria checks 4/4

DaVita's CEO is Javier Rodriguez, appointed in Jun 2019, has a tenure of 4.83 years. total yearly compensation is $2.98M, comprised of 40.2% salary and 59.8% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth $93.98M. The average tenure of the management team and the board of directors is 5.7 years and 4.8 years respectively.

Key information

Javier Rodriguez

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage	40.2%
CEO tenure	4.8yrs
CEO ownership	0.8%
Management average tenure	5.7yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Javier Rodriguez's remuneration changed compared to DaVita's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$692m
Sep 30 2023	n/a	n/a	US$596m
Jun 30 2023	n/a	n/a	US$454m
Mar 31 2023	n/a	n/a	US$500m
Dec 31 2022	US$3m	US$1m	US$547m
Sep 30 2022	n/a	n/a	US$680m
Jun 30 2022	n/a	n/a	US$834m
Mar 31 2022	n/a	n/a	US$903m
Dec 31 2021	US$3m	US$1m	US$978m
Sep 30 2021	n/a	n/a	US$984m
Jun 30 2021	n/a	n/a	US$883m
Mar 31 2021	n/a	n/a	US$791m
Dec 31 2020	US$73m	US$1m	US$783m
Sep 30 2020	n/a	n/a	US$832m
Jun 30 2020	n/a	n/a	US$824m
Mar 31 2020	n/a	n/a	US$816m
Dec 31 2019	US$17m	US$1m	US$705m
Sep 30 2019	n/a	n/a	US$623m
Jun 30 2019	n/a	n/a	US$548m
Mar 31 2019	n/a	n/a	US$551m
Dec 31 2018	US$8m	US$900k	US$616m
Sep 30 2018	n/a	n/a	US$617m
Jun 30 2018	n/a	n/a	US$698m
Mar 31 2018	n/a	n/a	US$652m
Dec 31 2017	US$8m	US$900k	US$909m

Compensation vs Market: Javier's total compensation ($USD2.98M) is below average for companies of similar size in the UK market ($USD5.62M).

Compensation vs Earnings: Javier's compensation has been consistent with company performance over the past year.

CEO

Javier Rodriguez (52 yo)

4.8yrs

Tenure

US$2,984,581

Compensation

Mr. Javier J. Rodriguez serves as an Independent Director at Gilead Sciences, Inc. since June 15, 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rod...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Javier Rodriguez	CEO & Executive Director	4.8yrs	US$2.98m	0.80% $ 94.0m
Joel Ackerman	CFO & Treasurer	7.2yrs	US$4.70m	0.16% $ 18.8m
Kathleen Waters	Chief Legal & Public Affairs Officer	7.9yrs	US$3.53m	0.068% $ 7.9m
James Hearty	Chief Compliance Officer	6.1yrs	US$1.66m	0.014% $ 1.6m
Michael Staffieri	Chief Operating Officer of Kidney Care	10.1yrs	US$6.92m	0.23% $ 26.9m
Christopher Berry	Group VP & Chief Accounting Officer	less than a year	no data	no data
Jim Gustafson	Vice President of Investor Relations	no data	no data	no data
Kenneth Smith	Chief People Officer	no data	no data	no data
Misha Palecek	Chief Transformation Officer of U.S. Kidney Care Business	no data	no data	no data
Jeffrey Giullian	Chief Medical Officer of Kidney Care	4.2yrs	no data	no data
Partha Das	Chief Medical Officer of DaVita International	5.7yrs	no data	no data
Mandy Hale	Chief Nursing Officer	3.8yrs	no data	no data

5.7yrs

Average Tenure

52yo

Average Age

Experienced Management: 0I7E's management team is seasoned and experienced (5.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Javier Rodriguez	CEO & Executive Director	4.8yrs	US$2.98m	0.80% $ 94.0m
John Nehra	Independent Director	23.4yrs	US$345.49k	0.089% $ 10.4m
Charles Berg	Director	17.1yrs	US$284.97k	0.029% $ 3.4m
Barbara Desoer	Independent Director	8.5yrs	US$367.47k	0.018% $ 2.1m
Phyllis Yale	Independent Director	7.8yrs	US$329.97k	0.017% $ 2.0m
Wendy Schoppert	Independent Director	less than a year	no data	0.00094% $ 110.1k
Pamela Arway	Independent Chair	14.9yrs	US$469.97k	0.027% $ 3.2m
Dennis Pullin	Independent Director	no data	no data	no data
Adam Schechter	Independent Director	1.6yrs	US$37.86k	0.0030% $ 350.1k
Jason Hollar	Independent Director	1.9yrs	US$144.10k	0.0040% $ 471.9k
Gregory Moore	Independent Director	2.6yrs	US$294.97k	0.0054% $ 633.4k

4.8yrs

Average Tenure

63yo

Average Age

Experienced Board: 0I7E's board of directors are considered experienced (4.8 years average tenure).

DaVita Management

Management criteria checks 4/4

Key information

Recent management updates

Davita Announces Dennis Pullin to Its Board of Directors

Chief Compliance Officer recently sold US$3.0m worth of stock

DaVita Inc. Announces Management Changes

Chief Legal & Public Affairs Officer recently sold US$1.0m worth of stock

Director recently sold US$108k worth of stock

Independent Director recently bought US$356k worth of stock

Recent updates

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

Chief Compliance Officer recently sold US$3.0m worth of stock

Full year 2023 earnings released: EPS: US$7.62 (vs US$5.88 in FY 2022)

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

Investor sentiment improves as stock rises 15%

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$2.70 (vs US$1.16 in 3Q 2022)

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 21%

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$1.96 (vs US$2.38 in 2Q 2022)

DaVita Inc. Announces Management Changes

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chief Legal & Public Affairs Officer recently sold US$1.0m worth of stock

First quarter 2023 earnings released: EPS: US$1.28 (vs US$1.68 in 1Q 2022)

Director recently sold US$108k worth of stock

Full year 2022 earnings released: EPS: US$5.88 (vs US$9.30 in FY 2021)

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Independent Director recently bought US$356k worth of stock

Second quarter 2022 earnings released: EPS: US$2.38 (vs US$2.76 in 2Q 2021)

Investor sentiment deteriorated over the past week

DaVita Inc. to Report Q3, 2022 Results on Oct 28, 2022

DaVita Inc. Appoints Adam H. Schechter to Board of Directors

Second quarter 2022 earnings released: EPS: US$2.38 (vs US$2.76 in 2Q 2021)

DaVita Inc. to Report Q2, 2022 Results on Aug 01, 2022

Chief Operating Officer of Kidney Care recently bought US$1.6m worth of stock

Independent Director recently sold US$226k worth of stock

DaVita Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings released: EPS: US$1.68 (vs US$2.18 in 1Q 2021)

DaVita Inc. to Report Q1, 2022 Results on May 05, 2022

DaVita Inc. Appoints Jason M. Hollar as Independent Director

Independent Director recently sold US$80k worth of stock

DaVita Inc. (NYSE:DVA) acquired 17 Dialysis Centers in United States.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

DaVita Inc. to Report Q4, 2021 Results on Feb 10, 2022

DaVita Inc. (NYSE:DVA) acquired MedSleuth, Inc.

Third quarter 2021 earnings released: EPS US$2.48 (vs US$1.31 in 3Q 2020)

Independent Director recently sold US$105k worth of stock

Second quarter 2021 earnings released: EPS US$2.76 (vs US$1.65 in 2Q 2020)

DaVita Inc. (NYSE:DVA) acquired a Dialysis Center in US.

Davita's China Affiliate to Invest in Hunan Fangsheng Pharma's Unit for 31.7% Stake

First quarter 2021 earnings released: EPS US$2.18 (vs US$1.84 in 1Q 2020)

Revenue misses expectations

Full year 2020 earnings released: EPS US$6.54 (vs US$4.61 in FY 2019)

Kyros Law Files Legal Claims on Behalf of Davita Inc Investors

DaVita Inc. to Report Q4, 2020 Results on Feb 11, 2021

Renalytix AI plc and DaVita Announce Partnership

DaVita Inc. Announces Management Changes, with Effect from December 15, 2020

Chief Legal Officer recently sold US$1.1m worth of stock

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

DaVita Inc. to Report Q3, 2020 Results on Oct 29, 2020

DaVita Inc. Announces the Retirement of Leanne M. Zumwalt, Group Vice President, Government Affairs

An unknown buyer acquired RMS Lifeline, Inc. from DaVita Inc. (NYSE:DVA).

DaVita Inc. to Report Q2, 2020 Results on Jul 30, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age